- Home
- TWST
as 05-08-2025 4:00pm EST
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.3B | IPO Year: | 2018 |
| Target Price: | $49.10 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $29.76 - $60.90 | Next Earning Date: | 05-05-2025 |
| Revenue: | $347,680,000 | Revenue Growth: | 25.30% |
| Revenue Growth (this year): | 22.54% | Revenue Growth (next year): | 17.77% |
Stock Insider Trading Activity of Twist Bioscience Corporation (TWST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Green Paula | TWST | SVP of Human Resources | May 5 '25 | Sell | $37.65 | 1,101 | $41,453.75 | 129,380 | |
| Cho Dennis | TWST | See Remarks | May 5 '25 | Sell | $37.65 | 689 | $25,941.54 | 110,849 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | May 5 '25 | Sell | $37.65 | 162 | $6,099.46 | 51,272 | |
| Finn Patrick John | TWST | President and COO | May 5 '25 | Sell | $37.65 | 2,800 | $105,422.80 | 262,660 | |
| Finn Patrick John | TWST | President and COO | Apr 23 '25 | Sell | $40.00 | 2,058 | $82,309.71 | 262,660 | |
| Laponis Adam | TWST | Chief Financial Officer | Apr 9 '25 | Sell | $34.97 | 2,542 | $88,887.13 | 106,954 | |
| Leproust Emily M. | TWST | Chief Executive Officer | Apr 2 '25 | Sell | $38.73 | 492 | $19,056.64 | 660,474 | |
| Green Paula | TWST | SVP of Human Resources | Apr 2 '25 | Sell | $38.73 | 140 | $5,422.62 | 129,380 | |
| Cho Dennis | TWST | See Remarks | Apr 2 '25 | Sell | $38.73 | 124 | $4,802.89 | 110,849 | |
| Finn Patrick John | TWST | President and COO | Apr 2 '25 | Sell | $38.73 | 206 | $7,979.00 | 262,660 |
Latest Twist Bioscience Corporation News
TWST Breaking Stock News: Dive into TWST Ticker-Specific Updates for Smart Investing
Business Wire
11 hours ago
Twist Bioscience and Ginkgo Bioworks Revise Collaboration
Simply Wall St.
3 days ago
Twist Bioscience Second Quarter 2025 Earnings: EPS Misses Expectations
GuruFocus.com
3 days ago
Twist Bioscience Corp (TWST) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic ...
Thomson Reuters StreetEvents
3 days ago
Q2 2025 Twist Bioscience Corp Earnings Call
Zacks
3 days ago
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
MT Newswires
3 days ago
Twist Bioscience Launches Atlas Data Storage as Independent Company With $155M Backing
MT Newswires
3 days ago
Twist Bioscience Fiscal Q2 Loss Narrows, Revenue Rises; 2025 Sales Outlook Maintained
Associated Press Finance
3 days ago
Twist Bioscience: Fiscal Q2 Earnings Snapshot
Compare TWST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TWST Twist Bioscience Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.